← Leaderboards
Luis A Martinez-Lemus
University Of Missouri-Columbia
$7,854,185
Attributed
$12,162,822
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,162,822 · 6
By mechanism
R01$11,290,523 · 5
P01$872,299 · 1
Top collaborators
- Jaume Padilla12 shared
- Camila Margarita Manrique Acevedo2 shared
- Shawn Brady Bender1 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Guido Lastra$838,510
- Michael A Hill$5,763,438
- Adam T Whaley Connell$146,350
- Erik J. Behringer$2,756,893
- Rene Gabriel Cortese$1,494,629
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsPreventCardiovascular SystemProductionCardiovascular DiseasesArteriesInnovationResponseTissuesAnimal ModelMethodologyVasodilator AgentsResistanceExperimental StudyGenetic ManipulationLoss Of FunctionMediatingPublishingMatrix MetalloproteinasesDiabetes MellitusStructureLifeClinical TrialsMolecular
Grant awards (26)
Tissue transglutaminase as a therapeutic target for arterial stiffening and hypertension in obesity$685,654
R01 · FY2025 · HL · contact PI
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$681,547
R01 · FY2025 · HL · contact PI
SGLT2 inhibition as a therapeutic strategy to reverse arterial stiffening in aging$591,486
R01 · FY2025 · AG
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$667,915
R01 · FY2024 · HL · contact PI
Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes$646,166
R01 · FY2024 · HL · contact PI
SGLT2 inhibition as a therapeutic strategy to reverse arterial stiffening in aging$617,681
R01 · FY2024 · AG
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$681,547
R01 · FY2023 · HL · contact PI
Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes$679,698
R01 · FY2023 · HL · contact PI
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$681,547
R01 · FY2022 · HL · contact PI
Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes$679,698
R01 · FY2022 · HL · contact PI
Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes$693,303
R01 · FY2021 · HL · contact PI
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$679,426
R01 · FY2021 · HL · contact PI
Mechanisms of Microvascular Remodeling Progression$377,433
R01 · FY2019 · HL · contact PI
Mechanisms of Microvascular Remodeling Progression$377,632
R01 · FY2018 · HL · contact PI
Mechanisms of Microvascular Remodeling Progression$377,826
R01 · FY2017 · HL · contact PI
Mechanisms of Microvascular Remodeling Progression$371,058
R01 · FY2016 · HL · contact PI
Imaging and Information Technology Core$166,387
P01 · FY2014 · HL · contact PI
Mechanisms of Microvascular Remodeling Progression$343,587
R01 · FY2013 · HL · contact PI
Imaging and Information Technology Core$159,705
P01 · FY2013 · HL · contact PI
Mechanisms of microvascular remodeling progression$361,191
R01 · FY2012 · HL · contact PI
Imaging and Information Technology Core$171,183
P01 · FY2012 · HL · contact PI
Mechanisms of microvascular remodeling progression$365,113
R01 · FY2011 · HL · contact PI
Imaging and Information Technology Core$174,855
P01 · FY2011 · HL · contact PI
Mechanisms of microvascular remodeling progression$365,379
R01 · FY2010 · HL · contact PI
Imaging and Information Technology Core$200,169
P01 · FY2010 · HL · contact PI
Mechanisms of microvascular remodeling progression$365,636
R01 · FY2009 · HL · contact PI